Literature DB >> 25487733

Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice.

Fang Ba1, W R Wayne Martin2.   

Abstract

BACKGROUND: Accurate diagnosis of Parkinson disease (PD) and other degenerative parkinsonian syndromes is important for management and prognostic purposes. Diagnosis can be challenging in early disease and in atypical cases.
METHODS: We reviewed the literature on the application of dopamine transporter single-photon emission computed tomography (DAT-SPECT) in degenerative parkinsonism and related disorders as a diagnostic tool.
RESULTS: The use of DAT-SPECT shows some utility in the early diagnosis of PD and differentiation from other non-degenerative parkinsonian disorders (i.e. essential tremor, dystonic tremor, drug-induced and in most cases of psychogenic parkinsonism), since it can accurately detect the presynaptic dopaminergic deficit. The test has been shown to have high sensitivity/specificity by multiple studies. DAT imaging may also have some prognostic value for disease progression. However, it has limited value in differentiating among degenerative causes of parkinsonism. DAT imaging has some limitations. In most studies, true test accuracy is unknown since the gold standard is clinical diagnosis by a movement disorders neurologist. Therefore, the sensitivity of the test cannot exceed that of the clinical diagnosis. In addition, false negative scans occur and highlight the need for clinical follow-up.
CONCLUSION: Clinical assessment remains the most important aspect in evaluating these patients. DAT-SPECT is a sensitive modality to detect nigrostriatal degeneration. In spite of increasing data using this technique, however, more long-term clinical studies are required to determine how DAT-SPECT scan can guide decision-making.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dopamine transporter; Parkinson's disease; Parkinsonism; SPECT; Tremor

Mesh:

Substances:

Year:  2014        PMID: 25487733     DOI: 10.1016/j.parkreldis.2014.11.007

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  40 in total

Review 1.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

2.  Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism.

Authors:  Elina Mäkinen; Juho Joutsa; Jarkko Johansson; Maija Mäki; Marko Seppänen; Valtteri Kaasinen
Journal:  J Neural Transm (Vienna)       Date:  2016-06-20       Impact factor: 3.575

Review 3.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 4.  Biomarkers for Parkinson's Disease: How Good Are They?

Authors:  Tianbai Li; Weidong Le
Journal:  Neurosci Bull       Date:  2019-10-23       Impact factor: 5.203

5.  Alterations in the reduced pteridine contents in the cerebrospinal fluids of LRRK2 mutation carriers and patients with Parkinson's disease.

Authors:  Hiroshi Ichinose; Ken-Ichi Inoue; Shinobu Arakawa; Yuki Watanabe; Hiroki Kurosaki; Shoko Koshiba; Eldbjorg Hustad; Masahiko Takada; Jan O Aasly
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

6.  Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings.

Authors:  Charles H Adler; Brittany N Dugger; Joseph G Hentz; Michael L Hinni; David G Lott; Erika Driver-Dunckley; Shyamal Mehta; Geidy Serrano; Lucia I Sue; Amy Duffy; Anthony Intorcia; Jessica Filon; Joel Pullen; Douglas G Walker; Thomas G Beach
Journal:  Mov Disord       Date:  2016-01-22       Impact factor: 10.338

7.  Cocaine analogue conjugated magnetic nanoparticles for labeling and imaging dopaminergic neurons.

Authors:  Mike Jeon; Guanyou Lin; Zachary R Stephen; Josey E Vechey; Manjot Singh; Richard Revia; Amy Hauck Newman; Diana Martinez; Miqin Zhang
Journal:  Biomater Sci       Date:  2020-06-09       Impact factor: 6.843

8.  MIBG Myocardial Scintigraphy Identifies Premotor PD/DLB During a Negative DAT Scan Period: Second Report.

Authors:  Ryuji Sakakibara; Fuyuki Tateno; Yosuke Aiba; Tsuyoshi Ogata; Masahiko Kishi; Hitoshi Terada; Tsutomu Inaoka; Tomoya Nakatsuka; Katsuyoshi Matsuoka
Journal:  Mov Disord Clin Pract       Date:  2018-11-09

9.  Spatial Normalization Using Early-Phase [18F]FP-CIT PET for Quantification of Striatal Dopamine Transporter Binding.

Authors:  Sungwoo Bae; Hongyoon Choi; Wonseok Whi; Jin Chul Paeng; Gi Jeong Cheon; Keon Wook Kang; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2020-10-13

10.  Assessment of Motor Dysfunction with Virtual Reality in Patients Undergoing [123I]FP-CIT SPECT/CT Brain Imaging.

Authors:  Jeanne P Vu; Ghiam Yamin; Zabrina Reyes; Alex Shin; Alexander Young; Irene Litvan; Pengtao Xie; Sebastian Obrzut
Journal:  Tomography       Date:  2021-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.